vs
艾伯维（ABBV）与Addus HomeCare Corp（ADUS）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Addus HomeCare Corp的44.5倍（$16.6B vs $373.1M）。艾伯维净利率更高（10.9% vs 8.0%，领先2.9%）。Addus HomeCare Corp同比增速更快（25.6% vs 10.0%）。艾伯维自由现金流更多（$4.9B vs $16.1M）。过去两年艾伯维的营收复合增速更高（16.2% vs 15.3%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Addus HomeCare Corp是一家总部位于美国的家庭护理服务提供商，主要为老年人、残障人士及慢性病患者提供个人护理、居家健康支持、临终关怀等服务，业务覆盖美国多个州，合作方包括政府支付机构、私营保险公司及个人客户。
ABBV vs ADUS — 直观对比
营收规模更大
ABBV
是对方的44.5倍
$373.1M
营收增速更快
ADUS
高出15.5%
10.0%
净利率更高
ABBV
高出2.9%
8.0%
自由现金流更多
ABBV
多$4.9B
$16.1M
两年增速更快
ABBV
近两年复合增速
15.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $373.1M |
| 净利润 | $1.8B | $29.8M |
| 毛利率 | 72.6% | 33.1% |
| 营业利润率 | 27.3% | 11.3% |
| 净利率 | 10.9% | 8.0% |
| 营收同比 | 10.0% | 25.6% |
| 净利润同比 | 8354.5% | 52.5% |
| 每股收益（稀释后） | $1.02 | $1.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVADUS
| Q4 25 | $16.6B | $373.1M | ||
| Q3 25 | $15.8B | $362.3M | ||
| Q2 25 | $15.4B | $349.4M | ||
| Q1 25 | $13.3B | $337.7M | ||
| Q4 24 | $15.1B | $297.1M | ||
| Q3 24 | $14.5B | $289.8M | ||
| Q2 24 | $14.5B | $286.9M | ||
| Q1 24 | $12.3B | $280.7M |
净利润ABBVADUS
| Q4 25 | $1.8B | $29.8M | ||
| Q3 25 | $186.0M | $22.8M | ||
| Q2 25 | $938.0M | $22.1M | ||
| Q1 25 | $1.3B | $21.2M | ||
| Q4 24 | $-22.0M | $19.5M | ||
| Q3 24 | $1.6B | $20.2M | ||
| Q2 24 | $1.4B | $18.1M | ||
| Q1 24 | $1.4B | $15.8M |
毛利率ABBVADUS
| Q4 25 | 72.6% | 33.1% | ||
| Q3 25 | 66.4% | 32.2% | ||
| Q2 25 | 71.8% | 32.6% | ||
| Q1 25 | 70.0% | 31.9% | ||
| Q4 24 | 70.9% | 34.2% | ||
| Q3 24 | 70.9% | 31.8% | ||
| Q2 24 | 70.9% | 32.5% | ||
| Q1 24 | 66.7% | 31.4% |
营业利润率ABBVADUS
| Q4 25 | 27.3% | 11.3% | ||
| Q3 25 | 12.1% | 9.1% | ||
| Q2 25 | 31.7% | 9.4% | ||
| Q1 25 | 28.0% | 9.0% | ||
| Q4 24 | -9.9% | 9.1% | ||
| Q3 24 | 26.5% | 9.0% | ||
| Q2 24 | 27.6% | 9.1% | ||
| Q1 24 | 22.7% | 8.4% |
净利率ABBVADUS
| Q4 25 | 10.9% | 8.0% | ||
| Q3 25 | 1.2% | 6.3% | ||
| Q2 25 | 6.1% | 6.3% | ||
| Q1 25 | 9.6% | 6.3% | ||
| Q4 24 | -0.1% | 6.6% | ||
| Q3 24 | 10.8% | 7.0% | ||
| Q2 24 | 9.5% | 6.3% | ||
| Q1 24 | 11.1% | 5.6% |
每股收益（稀释后）ABBVADUS
| Q4 25 | $1.02 | $1.62 | ||
| Q3 25 | $0.10 | $1.24 | ||
| Q2 25 | $0.52 | $1.20 | ||
| Q1 25 | $0.72 | $1.16 | ||
| Q4 24 | $-0.03 | $1.06 | ||
| Q3 24 | $0.88 | $1.10 | ||
| Q2 24 | $0.77 | $1.10 | ||
| Q1 24 | $0.77 | $0.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | — |
| 总债务越低越好 | $58.9B | $121.0M |
| 股东权益账面价值 | $-3.3B | $1.1B |
| 总资产 | $134.0B | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资ABBVADUS
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | — | ||
| Q1 25 | $5.2B | $97.0M | ||
| Q4 24 | $5.6B | $98.9M | ||
| Q3 24 | $7.3B | $222.9M | ||
| Q2 24 | $13.2B | $173.3M | ||
| Q1 24 | $18.1B | $76.7M |
总债务ABBVADUS
| Q4 25 | $58.9B | $121.0M | ||
| Q3 25 | $63.0B | $150.6M | ||
| Q2 25 | $63.0B | $169.1M | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | $218.4M | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVADUS
| Q4 25 | $-3.3B | $1.1B | ||
| Q3 25 | $-2.6B | $1.0B | ||
| Q2 25 | $-183.0M | $1.0B | ||
| Q1 25 | $1.4B | $995.4M | ||
| Q4 24 | $3.3B | $970.5M | ||
| Q3 24 | $6.0B | $947.6M | ||
| Q2 24 | $6.8B | $921.7M | ||
| Q1 24 | $8.0B | $725.1M |
总资产ABBVADUS
| Q4 25 | $134.0B | $1.4B | ||
| Q3 25 | $133.9B | $1.4B | ||
| Q2 25 | $137.2B | $1.4B | ||
| Q1 25 | $136.2B | $1.4B | ||
| Q4 24 | $135.2B | $1.4B | ||
| Q3 24 | $143.4B | $1.2B | ||
| Q2 24 | $141.9B | $1.1B | ||
| Q1 24 | $148.9B | $1.0B |
负债/权益比ABBVADUS
| Q4 25 | — | 0.11× | ||
| Q3 25 | — | 0.14× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | 0.23× | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $16.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 4.3% |
| 资本支出强度资本支出/营收 | 2.0% | 0.7% |
| 现金转化率经营现金流/净利润 | 2.87× | 0.63× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $103.8M |
8季度趋势，按日历期对齐
经营现金流ABBVADUS
| Q4 25 | $5.2B | $18.8M | ||
| Q3 25 | $7.0B | $51.3M | ||
| Q2 25 | $5.2B | $22.5M | ||
| Q1 25 | $1.6B | $18.9M | ||
| Q4 24 | $7.0B | $10.4M | ||
| Q3 24 | $5.4B | $48.5M | ||
| Q2 24 | $2.3B | $18.8M | ||
| Q1 24 | $4.0B | $38.7M |
自由现金流ABBVADUS
| Q4 25 | $4.9B | $16.1M | ||
| Q3 25 | $6.6B | $49.3M | ||
| Q2 25 | $4.9B | $21.3M | ||
| Q1 25 | $1.4B | $17.1M | ||
| Q4 24 | $6.8B | $8.7M | ||
| Q3 24 | $5.2B | $46.6M | ||
| Q2 24 | $2.0B | $17.7M | ||
| Q1 24 | $3.8B | $37.3M |
自由现金流率ABBVADUS
| Q4 25 | 29.4% | 4.3% | ||
| Q3 25 | 42.1% | 13.6% | ||
| Q2 25 | 31.7% | 6.1% | ||
| Q1 25 | 10.5% | 5.1% | ||
| Q4 24 | 44.7% | 2.9% | ||
| Q3 24 | 35.9% | 16.1% | ||
| Q2 24 | 14.0% | 6.2% | ||
| Q1 24 | 31.3% | 13.3% |
资本支出强度ABBVADUS
| Q4 25 | 2.0% | 0.7% | ||
| Q3 25 | 2.4% | 0.5% | ||
| Q2 25 | 1.7% | 0.4% | ||
| Q1 25 | 1.8% | 0.6% | ||
| Q4 24 | 1.9% | 0.6% | ||
| Q3 24 | 1.7% | 0.7% | ||
| Q2 24 | 1.7% | 0.4% | ||
| Q1 24 | 1.6% | 0.5% |
现金转化率ABBVADUS
| Q4 25 | 2.87× | 0.63× | ||
| Q3 25 | 37.76× | 2.24× | ||
| Q2 25 | 5.49× | 1.02× | ||
| Q1 25 | 1.27× | 0.89× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | 3.49× | 2.41× | ||
| Q2 24 | 1.66× | 1.04× | ||
| Q1 24 | 2.95× | 2.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
ADUS
| Personal Care | $286.0M | 77% |
| Hospice | $70.0M | 19% |
| Home Health | $17.1M | 5% |
